George Lundberg, MD Editor in Chief at Cancer Commons

  • March 8, 2022  

    Immunotherapy Before Targeted Therapy Extends OS in Metastatic Melanoma Bookmark

    George Lundberg, MD

    As reported by Healio, immunotherapy followed by targeted therapy improved overall survival in a clinical trial with metastatic melanoma patients.

    .

  • February 18, 2022  

    Learn More About Qualifying for Clinical Trials Bookmark

    George Lundberg, MD

    Clinical trials can be of great importance for patients with cancer. Here is some sound background information from Cancer Commons partner Let’s Win! Pancreatic Cancer.

    .

  • February 18, 2022  

    Mental Health and Pancreatic Cancer Bookmark

    George Lundberg, MD

    Coping with a potentially lethal cancer presents many serious challenges. This article from Cancer Commons partner Let’s Win! Pancreatic Cancer might help.

    .

  • February 18, 2022  

    Palliative Care Options for a Young Adult Patient with a Diffuse Intrinsic Pontine Glioma Bookmark

    George Lundberg, MD

    This clinical case study published in the scientific journal Cureus suggests that intelligent, compassionate, palliative care is likely the best approach to this very difficult brain tumor.

    .

  • February 18, 2022  

    DIPG All-In-Initiative Awards $35,000 Grant for Pediatric Brain Tumor Research Bookmark

    George Lundberg, MD

    As announced by Cancer Commons partner the Musella Foundation For Brain Tumor Research & Information, Inc., a collaboration of groups has announced funding to support research into possible treatments for pediatric diffuse intrinsic pontine glioma (DIPG).

    .

  • February 18, 2022  

    Low-Cost Online Pharmacy Launches Bookmark

    George Lundberg, MD

    As outlined in this press release on PR Newswire, it is now possible to buy many expensive drugs at very inexpensive prices from a new online pharmacy.

    .

  • February 18, 2022  

    Olaparib Shows Promise for Castrate-Resistant Prostate Cancer Bookmark

    George Lundberg, MD

    This Business Wire press release announces results from a clinical trial indicating that adding the drug olaparib (brand name Lynparza) to treatment for castrate-resistant prostate cancer enhanced disease-free progression, regardless of biomarker status.

    .

  • February 18, 2022  

    Realistic Expectations After Prostate Cancer Treatment Bookmark

    George Lundberg, MD

    This story from The ASCO Post discusses how doctors can help ensure that patients have realistic expectations about outcomes after prostate cancer treatment.

    .

  • February 18, 2022  

    Chemotherapy: Before Surgery Vs. After Surgery Bookmark

    George Lundberg, MD

    According to this article from the Cochrane Database of Systematic Reviews, chemotherapy administered before surgery may be beneficial for people with advanced ovarian cancer.

    .

  • February 18, 2022  

    This New Ovarian Cancer Treatment Could Improve Survival Rates Bookmark

    George Lundberg, MD

    Recently approved by the U.S. Food and Drug Administration (FDA), the drug Cytalux is given to ovarian cancer patients to allow surgeons to recognize cancer cells more clearly, promoting more complete surgical removal of tumors. Learn more in this story from The Philadelphia Inquirer.

    .